Li Jing, Li Peng, Wang Jin-fen, Xi Yan-feng
Department of Pathology, Shanxi Tumor Hospital, Shanxi Medical University, Taiyuan 030013, China.
Department of Pathology, Shanxi Tumor Hospital, Shanxi Medical University, Taiyuan 030013, China. E-mail:
Zhonghua Bing Li Xue Za Zhi. 2013 Nov;42(11):748-52.
To study the expression of miR-16 and bcl-2 in T lymphoblastic lymphoma/leukemia (T-LBL/ALL) and its relationship to prognosis.
70 cases of T-LBL/ALL with follow-up data were studied by using immunohistochemical EnVision method for CD1a, CD3, cCD3, CD7, CD10, CD20, CD23, CD34, CD43, CD45RO, CD99, TDT, MPO, bcl-2 and Ki-67. The expression levels of miR-16 were examined by TaqMan real-time polymerase chain reaction (RT-PCR). Thirty cases of reactive lymph node were selected as control.
Among the 70 cases of T-LBL/ALL, the percentages of tumor cells expression of TDT, CD99, CD3, CD7, CD10, CD34, CD1a, cCD3, bcl-2, CD45RO and CD43 were 94.3% (66/70), 94.3% (66/70), 68.6% (48/70), 92.9% (65/70), 32.9% (23/70), 24.3% (17/70), 40.0% (28/70), 51.4% (36/70), 34.3% (24/70), 37.1% (26/70), and 48.6% (34/70). Separately, while tumor cells expression of MPO, CD20 and CD23 was all negative. A figure of Ki-67 expression > 80% was found in 24 cases and ≤ 80% in 46 cases. The expression of miR-16 was up-regulated in T-LBL/ALL, and it was 5.07 times of the reactive lymph node(P = 0.001). The high expression group of miR-16 was significantly correlated with longer over survival (P = 0.041). The prognosis of negative bcl-2 group was better than bcl-2 positive one(P = 0.904). The relationship of miR-16 and bcl-2 was significant(P = 0.042,χ(2) = 4.147). Survival multivariate COX proportional hazard regression analysis revealed that the low expression of miR-16 might be a independent poor prognosis factor (P = 0.049).
While the high expression group of miR-16 has longer OS than that in low expression group. The prognosis of bcl-2 negative was better than bcl-2 positive. miR-16 may be a independent prognosis factor. The relationship of miR-16 and bcl-2 might suggested that gene regulation may be influenced by them.
研究miR-16和bcl-2在T淋巴母细胞淋巴瘤/白血病（T-LBL/ALL）中的表达及其与预后的关系。
采用免疫组织化学EnVision法检测70例有随访资料的T-LBL/ALL患者的CD1a、CD3、胞质CD3（cCD3）、CD7、CD10、CD20、CD23、CD34、CD43、CD45RO、CD99、末端脱氧核苷酸转移酶（TDT）、髓过氧化物酶（MPO）、bcl-2和Ki-67。采用TaqMan实时聚合酶链反应（RT-PCR）检测miR-16的表达水平。选取30例反应性淋巴结作为对照。
70例T-LBL/ALL患者中，肿瘤细胞表达TDT、CD99、CD3、CD7、CD10、CD34、CD1a、cCD3、bcl-2、CD45RO和CD43的比例分别为94.3%（66/70）、94.3%（66/70）、68.6%（48/70）、92.9%（65/70）、32.9%（23/70）、24.3%（17/70）、40.0%（28/70）、51.4%（36/70）、34.3%（24/70）、37.1%（26/70）和48.6%（34/70）。另外，肿瘤细胞MPO、CD20和CD23表达均为阴性。24例患者Ki-67表达>80%，46例≤80%。T-LBL/ALL中miR-16表达上调，是反应性淋巴结的5.07倍（P = 0.001）。miR-16高表达组总生存期明显延长（P = 0.041）。bcl-2阴性组预后优于bcl-2阳性组（P = 0.904）。miR-16与bcl-2的关系具有统计学意义（P = 0.042，χ² = 4.147）。生存多因素COX比例风险回归分析显示，miR-16低表达可能是独立的不良预后因素（P = 0.049）。
miR-16高表达组总生存期长于低表达组。bcl-2阴性者预后优于bcl-2阳性者。miR-16可能是独立的预后因素。miR-16与bcl-2的关系提示它们可能影响基因调控。
